The Omega-3 Protocol
Rhonda Patrick makes omega-3 fatty acids one of the few supplements with real longevity evidence: aim for an omega-3 index of 8% or higher. A higher index tracks with lower all-cause mortality in large studies; food sources like wild fish come first, and the well-absorbed triglyceride form beats cheap ethyl-ester fish oil. Higher doses carry a real, dose-dependent atrial fibrillation signal, so see the safety step below before matching a high-dose regimen.
Test your omega-3 index A red-blood-cell omega-3 index test; aim for 8% or higher (US average is far lower)
It is the only way to know if you are actually getting enough; response varies between people.
Get omega-3s from food first Several servings/week of wild, low-mercury fish (salmon, sardines, anchovies); salmon roe is rich in EPA/DHA
Food delivers omega-3s in a well-absorbed form alongside other nutrients.
Add a quality fish oil to reach target ~2 g/day EPA+DHA for most to move the index toward 8%; Patrick personally takes ~4 g, EPA am / DHA pm. See the dose-response safety step below before matching that higher amount.
Most people cannot hit target from diet alone; supplementing closes the gap.
Understand how atrial fibrillation risk scales with dose A meta-analysis of 7 randomized trials (n=81,210) found omega-3 supplementation raised atrial fibrillation risk overall (hazard ratio 1.25, 95% CI 1.07 to 1.46). The risk was still significantly elevated at 1 g/day or less (hazard ratio 1.12, 1.03 to 1.22), and rose further above 1 g/day (hazard ratio 1.49, 1.04 to 2.15); each additional 1 g/day tracked with about 11% more risk in a meta-regression (hazard ratio 1.11, 1.06 to 1.15).
This risk is not confined to high-dose prescription trials; it is significant even at 1 g/day or less. Anyone at or above 2 g/day, including Patrick's own ~4 g/day, should weigh this against the benefit rather than assume more is automatically better.
See how the drug trials cut both ways REDUCE-IT (4 g/day of the prescription drug icosapent ethyl, in statin-treated adults with established heart disease or diabetes plus risk factors and triglycerides 135 to 499 mg/dL) cut a composite of cardiovascular events from 22.0% to 17.2% (hazard ratio 0.75), but also raised hospitalization for atrial fibrillation (3.1% versus 2.1%). STRENGTH (4 g/day omega-3 carboxylic acids, n=13,078) found no benefit on a similar composite endpoint and was stopped for futility, with new-onset atrial fibrillation clearly more common (hazard ratio 1.69). VITAL (1 g/day, closer to a typical supplement dose, n=25,871, general population) found no significant effect on its main cardiovascular endpoint (hazard ratio 0.92); a secondary finding on heart attacks (hazard ratio 0.72) was flagged by its own authors as hypothesis-generating, not a confirmed result.
REDUCE-IT's benefit is a prescription-drug result in a selected high-risk group, not a general 'fish oil cuts heart attacks' claim, and even that trial's benefit is debated: some researchers argue part of it may reflect the mineral-oil placebo arm getting worse rather than the drug arm doing better, an unsettled dispute with no single number that resolves it.
See the cohort evidence on circulating omega-3 Separately, people with higher circulating omega-3 levels in their blood (their natural status, not an assigned supplement dose) show slightly lower rates of newly diagnosed atrial fibrillation across 17 prospective cohorts (n=54,799): EPA plus DHA linked to about a 7% lower rate.
This is a blood-level-in-observational-cohorts finding, distinct from the supplement-dose-in-randomized-trials findings above; it is a correlation, not proof of cause, and the two evidence types are being presented on purpose, not as a contradiction we missed.
Read your own bottle's actual EPA plus DHA dose Find the EPA line and the DHA line on the Supplement Facts panel and add them together; that sum, not the front-of-bottle '1000 mg' fish oil weight, is your real dose. A typical 1,000 mg fish oil capsule commonly delivers about 300 mg combined EPA plus DHA (about 180 mg EPA, 120 mg DHA).
The front-of-bottle number is total fish oil weight, not the active omega-3 dose, so most people underestimate how many capsules it takes to reach 1 to 2 grams of EPA plus DHA.
Choose triglyceride form, third-party tested Look for triglyceride form, low oxidation (TOTOX), and tested for mercury/PCBs; take with food
Cheap ethyl-ester and oxidised oils undercut the benefit; quality is not optional here.
Use algae oil if you do not eat fish Algae-based EPA/DHA is the best plant source; ALA from flax/walnuts converts poorly
Algae oil delivers EPA/DHA directly, unlike ALA which barely converts.
Retest after a few months Re-measure the index ~3 to 4 months after changing intake, and adjust dose
It confirms your dose is actually working and lets you fine-tune.
This protocol works from your actual levels. Testing partner coming soon.
- Omega-3 index test
We may earn a referral fee if you book testing through a future partner link; it will never affect which tests are listed here. This is not medical advice or a diagnosis.
EPA and DHA support cardiovascular health, brain function and cell-membrane fluidity, and a higher omega-3 index tracks with lower mortality across large prospective studies.
View sources
The Powerful Longevity Benefits of Omega-3 (Dr. Rhonda Patrick, FoundMyFitness)
Omega-3 Index: optimal levels and intake (FoundMyFitness)
Sauna and omega-3 in the foundational stack (FoundMyFitness topic library)
NIH Office of Dietary Supplements, Omega-3 Fatty Acids fact sheet (health professional)
Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM, Omega-3 fatty acids and atrial fibrillation, Circulation 2021;144(25):1981-1990
Bhatt DL, et al., REDUCE-IT, NEJM 2019;380(1):11-22
Nicholls SJ, et al., STRENGTH, JAMA 2020;324(22):2268-2280
Manson JE, et al., VITAL, NEJM 2019;380(1):23-32
Qian F, Tintle N, Jensen PN, et al., Circulating omega-3 fatty acids and incident atrial fibrillation, Journal of the American College of Cardiology 2023;82(4):336-349
Bostrom JA, Beckman JA, Berger JS, Summoning STRENGTH to Question the Placebo in REDUCE-IT, Circulation 2021
Olshansky B, Chung MK, Budoff MJ, et al., European Heart Journal Supplements 2020;22(Suppl J):J34-J48
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol is an independent platform. This protocol is based on the publicly available work of Rhonda Patrick and is not created, reviewed, endorsed by, or affiliated with Rhonda Patrick or FoundMyFitness.
Is this for you
- Anyone who eats little oily fish
- People focused on brain and heart healthspan
- Those who want evidence-led supplementation
- Vegans and vegetarians (via algae)
Cautions
- Higher intake carries a real dose-dependent atrial fibrillation signal, significant even at 1 g/day or less and higher above 1 g/day; if you have a history of atrial fibrillation, palpitations, or heart disease, talk to your doctor before matching a high-dose regimen like Patrick's ~4 g/day
- Icosapent ethyl, the drug studied in REDUCE-IT, is a prescription medication; this page does not recommend a dose of it
- Fish oil may prolong clotting time; if you take warfarin or another blood thinner, talk to your doctor before starting
- Very high doses (10g+/day) may raise arrhythmia risk in some people, and omega-3 trials in established cardiovascular disease have been mixed
- Quality varies enormously: ethyl-ester and oxidised fish oils undercut the benefit, so prioritise triglyceride form and third-party testing
- More is not automatically better; test, dose to target, and retest rather than mega-dosing blindly
- Educational only, not medical advice
Common questions
Some links earn us a commission. It never affects our picks or grades. See our affiliate disclosure.